Oragenics Announces Completion of Second Closing of $3.0 Million Preferred Stock Private Placement July 26, 2017
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE MKT Continued Listing Standard June 9, 2017
Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAACÂ Conference June 6, 2017
Oragenics Announces $3.0 Million Preferred Stock Private Placement and $2.4 Million Loan May 11, 2017
Oragenics Presents Engineering of Improved Lantibiotic Variants at American Society for Microbiology (ASM) Conference on Antibacterial Development December 15, 2016
U.S. FDA Grants Fast Track Designation for the Development of Oragenics’ AG013 for Oral Mucositis November 21, 2016
Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment August 30, 2016
